Table 4.

Detail of patients in whom lenvatinib was permanently discontinued due to toxicity

Patient	Reason for lenvatinib discontinuation
#1	Grade 3 alanine aminotransferase increase (6× ULN)
#2	Grade 2 colitis and fatigue, patient decision not to restart therapy
#3	30 kg weight loss, severe fatigue, and anorexia despite multiple dose reductions
#4	Important fatigue, weight loss, ECOG-PS 3 despite dose reductions
#5	Grade 2 proteinuria (3 grams/day) despite ARB
#6	Nephrotic syndrome
#7	Grade 3 vestibular disorder
#8	Proteinuria 5 grams/day, recurring after temporary treatment discontinuation and dose reduction
#9	Takotsubo cardiomyopathy with grade 4 left ventricular dysfunction and cardiogenic shock
#10	Grade 3 acute pancreatitis
#11	20 kg weight loss despite dose reduction
#12	Grade 4 PRES
#13	Grade 3 hand-foot syndrome, 2 grams/day proteinuria despite multiple dose reductions

Abbreviations: ARB, angiotensin II receptor blocker; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; PRES, posterior reversible encephalopathy syndrome; ULN, upper limit of normal.